Meet some of our speakers here and learn more about their presentations at the 23rd Congress of EHA.
More information to follow on a weekly basis.
Dr Tsvee Lapidot
Sunday, June 17 - Plenary Session 2
Healthy and malignant hematopoiesis in the bone marrow: Active cells in a dynamic environment
In this talk metabolic regulation of normal and leukemic stem cells in the bone marrow will be discussed.
In particular the roles of reactive oxygen species (ROS) and nitric oxide (NO) and their mode of action will be revealed.
Dr Charles Swanton
Saturday, June 16: EHA-ASH Joint Symposium
Cancer genetic heterogeneity fuels natural selection and adaptation of tumours in the face of tumour microenvironmental change and cancer therapies. This talk will consider how tumours adapt under selection pressures and how the immune system constrains tumour growth. Novel therapeutic approaches targeting cancer evolution and leveraging the immune microenvironment will be discussed.
Dr Giampaolo Merlini
Sunday, June 17: Plenary Session 2
Amyloidosis: The rapidly changing face of diagnosis and therapy in AL amyloidosis
Formidable advances have been made during the last decade in deciphering the molecular mechanisms underlying AL amyloidosis and in the management of this complex and dreadful disease.
The combination of biomarkers and imaging united with increased awareness led to earlier diagnosis with a positive impact on patients’ outcome. Novel drugs are enriching the therapeutic landscape and immunotherapies aimed at accelerating the reabsorption of amyloid deposits are under development. The future lies in risk-adapted combination of anti-clone therapy and anti-amyloid treatments, holding promise of further improving the outlook in this now treatable disease.
Dr Markus Müschen
Saturday, June 16: Plenary Session 1
Autoimmunity checkpoints as therapeutic targets in B-cell malignancies
Unlike other types of cancer, B-cell malignancies are susceptible to negative selection and cell death induced by hyperactive signaling from an autoreactive B-cell receptor. While targeted therapy of cancer typically focuses on agents to suppress activity of oncogenes, Markus Müschen and colleagues introduce a new concept of targeted hyperactivation with the goal to trigger autoimmunity checkpoints and cell death in B-cell tumors.